Three-Dimensional Models of Wild-Type and Mutated Forms of Cytochrome P450 14α-Sterol Demethylases from Aspergillus fumigatus and Candida albicans Provide Insights into Posaconazole Binding

ABSTRACT The cytochrome P450 sterol 14α-demethylase enzyme (CYP51) is the target of azole antifungals. Azoles block ergosterol synthesis, and thereby fungal growth, by binding in the active-site cavity of the enzyme and ligating the iron atom of the heme cofactor through a nitrogen atom of the azole. Mutations in and around the CYP51 active site have resulted in azole resistance. In this work, homology models of the CYP51 enzymes from Aspergillus fumigatus and Candida albicans were constructed based on the X-ray crystal structure of CYP51 from Mycobacterium tuberculosis. Using these models, binding modes for voriconazole (VOR), fluconazole (FLZ), itraconazole (ITZ), and posaconazole (POS) were predicted from docking calculations. Previous work had demonstrated that mutations in the vicinity of the heme cofactor had a greater impact on the binding of FLZ and VOR than on the binding of POS and ITZ. Our modeling data suggest that the long side chains of POS and ITZ occupy a specific channel within CYP51 and that this additional interaction, which is not available to VOR and FLZ, serves to stabilize the binding of these azoles to the mutated CYP51 proteins. The model also predicts that mutations that were previously shown to specifically impact POS susceptibility in A. fumigatus and C. albicans act by interfering with the binding of the long side chain.

[1]  R Sánchez,et al.  Advances in comparative protein-structure modelling. , 1997, Current opinion in structural biology.

[2]  J. Peterson,et al.  How similar are P450s and what can their differences teach us? , 1999, Archives of biochemistry and biophysics.

[3]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[4]  D. Sheehan,et al.  Current and Emerging Azole Antifungal Agents , 1999, Clinical Microbiology Reviews.

[5]  Cytochrome P450. , 1995, Current opinion in structural biology.

[6]  D. Sanglard,et al.  Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. , 2002, The Lancet. Infectious diseases.

[7]  M. Pfaller,et al.  In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. andCryptococcus neoformans , 2001, Antimicrobial Agents and Chemotherapy.

[8]  D. Loebenberg,et al.  Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. , 2003, The Journal of antimicrobial chemotherapy.

[9]  A. Sali,et al.  Large-scale protein structure modeling of the Saccharomyces cerevisiae genome. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  E. Mellado,et al.  A Point Mutation in the 14α-Sterol Demethylase Gene cyp51A Contributes to Itraconazole Resistance in Aspergillus fumigatus , 2003, Antimicrobial Agents and Chemotherapy.

[11]  M H Tarbit,et al.  Molecular modelling of lanosterol 14 alpha-demethylase (CYP51) from Saccharomyces cerevisiae via homology with CYP102, a unique bacterial cytochrome P450 isoform: quantitative structure-activity relationships (QSARs) within two related series of antifungal azole derivatives. , 1999, Journal of enzyme inhibition.

[12]  T. Poulos,et al.  Crystal structure of cytochrome P450 14α-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  D. Loebenberg,et al.  Mutations in Aspergillus fumigatus Resulting in Reduced Susceptibility to Posaconazole Appear To Be Restricted to a Single Amino Acid in the Cytochrome P450 14α-Demethylase , 2003, Antimicrobial Agents and Chemotherapy.

[14]  M. D. de Groot,et al.  Genetic Basis for Differential Activities of Fluconazole and Voriconazole against Candida krusei , 2003, Antimicrobial Agents and Chemotherapy.

[15]  D E McRee,et al.  Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. , 2000, Molecular cell.

[16]  C. Fattorusso,et al.  Construction of a model of the Candida albicans lanosterol 14-alpha-demethylase active site using the homology modelling technique. , 1998, Pharmaceutica acta Helvetiae.

[17]  Andrej ⩽ali,et al.  Comparative protein modeling by satisfaction of spatial restraints , 1995 .

[18]  G. Costantino,et al.  1,4-Benzothiazine and 1,4-benzoxazine imidazole derivatives with antifungal activity: a docking study. , 2002, Bioorganic & medicinal chemistry.

[19]  D. Loebenberg,et al.  A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). , 2000, The Journal of antimicrobial chemotherapy.

[20]  P. Marichal,et al.  Anti-Candida drugs--the biochemical basis for their activity. , 1987, Critical reviews in microbiology.

[21]  Wannian Zhang,et al.  A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals. , 2000, Journal of medicinal chemistry.

[22]  T. Poulos,et al.  The structure of the cytochrome p450BM-3 haem domain complexed with the fatty acid substrate, palmitoleic acid , 1997, Nature Structural Biology.

[23]  T. Poulos,et al.  Substrate recognition sites in 14alpha-sterol demethylase from comparative analysis of amino acid sequences and X-ray structure of Mycobacterium tuberculosis CYP51. , 2001, Journal of inorganic biochemistry.

[24]  E. Mellado,et al.  Identification of Two Different 14-α Sterol Demethylase-Related Genes (cyp51A and cyp51B) in Aspergillus fumigatus and Other Aspergillus species , 2001, Journal of Clinical Microbiology.

[25]  Guy H. Grant,et al.  Modeling cytochrome P450 14α demethylase (Candida albicans) from P450cam , 1994 .

[26]  C David Stout,et al.  Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 A resolution: evidence for multiple substrate binding modes. , 2003, Biochemistry.

[27]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[28]  G. Goldman,et al.  Multiple Resistance Mechanisms among Aspergillus fumigatus Mutants with High-Level Resistance to Itraconazole , 2003, Antimicrobial Agents and Chemotherapy.

[29]  J. Peterson,et al.  A close family resemblance: the importance of structure in understanding cytochromes P450. , 1998, Structure.

[30]  N. Shimma,et al.  Modeling, synthesis and biological activity of novel antifungal agents (1). , 1998, Bioorganic & medicinal chemistry letters.